Your browser doesn't support javascript.
loading
Inclusion body myositis: from genetics to clinical trials.
Nagy, Sara; Khan, Alaa; Machado, Pedro M; Houlden, Henry.
Affiliation
  • Nagy S; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK. s.nagy@ucl.ac.uk.
  • Khan A; Department of Neurology, University Hospital Basel, University of Basel, Basel, Switzerland. s.nagy@ucl.ac.uk.
  • Machado PM; Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, University College London, London, UK.
  • Houlden H; Molecular Diagnostic Unit, Clinical Laboratory Department, King Abdullah Medical City in Makkah, Mecca, Saudi Arabia.
J Neurol ; 270(3): 1787-1797, 2023 Mar.
Article de En | MEDLINE | ID: mdl-36399165
ABSTRACT
Inclusion body myositis (IBM) belongs to the group of idiopathic inflammatory myopathies and is characterized by a slowly progressive disease course with asymmetric muscle weakness of predominantly the finger flexors and knee extensors. The disease leads to severe disability and most patients lose ambulation due to lack of curative or disease-modifying treatment options. Despite some genes reported to be associated with hereditary IBM (a distinct group of conditions), data on the genetic susceptibility of sporadic IBM are very limited. This review gives an overview of the disease and focuses on the current genetic knowledge and potential therapeutic implications.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Myosite à inclusions / Myosite Limites: Humans Langue: En Journal: J Neurol Année: 2023 Type de document: Article Pays d'affiliation: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Myosite à inclusions / Myosite Limites: Humans Langue: En Journal: J Neurol Année: 2023 Type de document: Article Pays d'affiliation: Royaume-Uni
...